Related Experiment Video
Updated: Nov 21, 2025

Comparing Objective Conjunctival Hyperemia Grading and the Ocular Surface Disease Index Score in Dry Eye Syndrome During COVID-19
Published on: May 25, 2022
Hydroxychloroquine in the post-COVID-19 era: will this pandemic upset decades of clinical practice?
Lucie Pothen1, Halil Yildiz2, Mathilde Mbouck Samnick3
1Department of Internal Medicine and Infectious Diseases, Cliniques Universitaires Saint-Luc, Université de Louvain (UCLouvain), 10 avenue Hippocrate, 1200, Brussels, Belgium. lucie.pothen@uclouvain.be.
Abstract:
In the early stage of the COVID-19 pandemic, Belgian health authorities endorsed the interim guidelines for the treatment of COVID-19 pneumonia: hydroxychloroquine (HCQ) recommended for treatment of hospitalized patients with moderate to severe disease. As a growing number of patients were admitted, inevitably, our internal medicine team questioned the efficacy and safety of HCQ, especially with regard to cardiac side effects. In parallel with our concerns, data regarding the safety and efficacy of HCQ were published, with discordant results and debate in the medical community. Media coverage of the possible risks and benefits of HCQ use in COVID-19 also caused confusion amongst the public. In this Perspectives in Rheumatology article, we review the use and safety of HCQ in autoimmune disease and its putative efficacy and toxicity in COVID-19. Finally, we share our concern about the future of this widely used and inexpensive drug after the COVID-19 pandemic has passed.
More Related Videos
09:03Nasal Brushing Sampling and Processing Using Digital High Speed Ciliary Videomicroscopy – Adaptation for the COVID-19 Pandemic
Published on: November 7, 2020
09:36Halogenated Agent Delivery in Porcine Model of Acute Respiratory Distress Syndrome via an Intensive Care Unit Type Device
Published on: September 24, 2020
Related Concept Videos
Rheumatic Heart Disease III: Medical Management
Rheumatic Heart Disease IV: Nursing Management
Nephrotic Syndrome II : Assessment and Medical Management
Chronic Obstructive Pulmonary Disease-V: Management
Smoking Cessation
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
Pericarditis III: Medical Management